> >
Clinical Resources

Evidence-Based Myopia
Management Library

Clinical summaries, treatment guides, and evidence breakdowns — written for optometrists managing pediatric myopia.

All articles

Clinical reference library

🌍
Global Epidemiology · Interactive Data
Global Myopia Prevalence by Country
Prevalence rates across 15 countries, prescription severity distribution, and treatment product availability by region — cited clinical epidemiology.
Explore data →
Guidelines · April 2026 NEW
IMI 2025: Is Myopia Management Still Optional?
A clinical breakdown of the IMI 2025 White Papers — what the new global standard of care means for axial length monitoring, pre-myopia intervention, and combination therapy.
8 min readRead article →
Treatment · April 2026
MiSight® vs Stellest® — Efficacy Comparison
RCT-sourced head-to-head comparison of the two leading optical myopia control modalities — mechanisms, efficacy data, patient selection, and practical prescribing guidance.
6 min readRead article →
Pharmacology · April 2026
Atropine 0.01% vs 0.025% vs 0.05% — Clinical Outcomes
LAMP study and ATOM2 dose-response data with side effect profiles, rebound risk comparison, and prescribing guidance for each concentration.
7 min readRead article →
Diagnostics · April 2026
Axial Length Growth Chart — Clinical Reference
How to use axial length growth charts in clinical practice — normative curves, growth rate benchmarks, the 26mm threshold, and how to plot individual patients against population norms.
5 min readRead article →
Parent Guide · April 2026
Why Is My Child's Myopia Getting Worse?
The eye continues to grow during childhood — that's the real driver. What causes it, how fast is too fast, and when to act.
5 min readRead article →
Treatment · April 2026
Best Myopia Treatment for Children (2026)
MiSight®, Stellest®, ortho-K, atropine — a head-to-head efficacy comparison with real trial numbers to help you choose.
6 min readRead article →
Guidelines · April 2026
When Should Myopia Treatment Start?
The IMI 2025 consensus: earlier is better, especially under 10. The clinical triggers, the cost of waiting, and the questions to ask your OD.
5 min readRead article →
Tools · April 2026
Myopia Management Software for Optometry Practices
How digital tools are changing myopia management workflows — what to look for, and how MyopiaTracker fits into clinical practice.
4 min readRead article →
Patient Education · April 2026
Can Myopia Be Reversed?
Almost never — but progression absolutely can be slowed. Evidence-based breakdown of what actually works, and why eye exercises don't.
5 min readRead article →
Risk & Outcomes · April 2026
Will Myopia Cause Blindness?
Most people with myopia don't go blind — but risk rises with axial length. Clear breakdown of real complication risks by AL and diopter.
5 min readRead article →
Diagnostics · April 2026
Is Myopia Getting Worse Too Fast?
Normal vs dangerous progression rates by age — in axial length and diopters. Is going from −2 to −5 in two years actually dangerous?
5 min readRead article →
Parent Guide · April 2026
What Causes Myopia?
Genetics, outdoor time, and near work — the three-way interaction driving the global myopia epidemic, and what parents can do.
4 min readRead article →
Parent Guide · April 2026
Does Screen Time Cause Myopia?
Screen time is associated with myopia — but probably not for the reason you think. The outdoor light factor explains most of the risk.
4 min readRead article →
Patient FAQ · April 2026
Should I Wear Glasses All the Time?
Wearing glasses doesn't make myopia worse. Not wearing them doesn't make it better. Standard glasses don't affect progression at all.
3 min readRead article →
Evidence Check · April 2026
Do Eye Exercises Work for Myopia?
Eye exercises improve eye strain but cannot change axial length. No RCT shows they slow myopia. Here's the honest, evidence-based answer.
4 min readRead article →
Patient Education · April 2026
When Does Myopia Stop Progressing?
Typically stabilises in the late teens to early 20s — but earlier onset means later stabilisation and higher final prescription.
4 min readRead article →
Treatment Hub · April 2026
Best Myopia Treatments Ranked (2026)
Stellest 67%, MiSight 55%, ortho-K 50%, atropine 30–58% — every evidence-based treatment with real RCT numbers, in one place.
6 min readRead article →
Adult Myopia · April 2026
Is LASIK Safe for Myopia?
LASIK corrects vision but doesn't reduce axial length or structural risk. What it does and doesn't do — and who qualifies.
5 min readRead article →
Global Epidemiology · April 2026
Myopia in China
52.7% paediatric prevalence — the global epicentre. Age-group breakdown, COVID effect, and treatment patterns.
8 min readRead article →
Global Epidemiology · April 2026
Myopia in India
13% nationally but 48% urban — rising rapidly. Projected 2nd largest myopia population by 2050.
6 min readRead article →
Global Epidemiology · April 2026
Myopia in the United States
42% prevalence, doubled since the 1970s. MiSight® FDA-approved, ethnic variation, and the regulatory landscape.
6 min readRead article →
Global Epidemiology · April 2026
Myopia in South Korea
96.5% in young Seoul males — understanding the data, methodology caveats, and clinical implications.
5 min readRead article →
Global Epidemiology · April 2026
Myopia in Australia
18% overall, 60%+ in East Asian-descent children. Sydney Myopia Study and outdoor light evidence.
5 min readRead article →
Treatment · May 2026
Treatment Efficacy: What the Percentages Mean
Interpreting efficacy data from DIMS, MiSight, and atropine trials. Why 78% and 59% are not directly comparable, and what matters for your patient.
6 min readRead article →
Patient Education · May 2026
Living with High Myopia (≥−6D)
Visual function, driving safety, complication risk, and activity guidance for patients with high myopia. Evidence-based perspective on quality of life.
7 min readRead article →
Guidelines · May 2026
Myopia Progression in Adults (20s–30s)
Does myopia still progress after 18? Atropine efficacy in adults, ortho-K progression, and when to recommend continued monitoring and treatment.
8 min readRead article →
Patient Education · May 2026
The Blue Light Myth: What Actually Works for Screen Time
Blue-light glasses don't slow myopia. What the RCTs actually show. The real protective factor (hint: it's outdoor time), and honest talk about screen use.
5 min readRead article →
Treatment · May 2026
Ortho-K Correction Limits: Who Qualifies?
Prescription range, corneal topography requirements, and the clinical thresholds that determine orthokeratology candidacy. When to refer and when to fit.
6 min readRead article →
Pharmacology · May 2026
Atropine for Myopia in Adults: The Evidence
Is atropine effective after age 18? A review of adult trial data, off-label use considerations, and what the evidence actually supports for adult myopia control.
7 min readRead article →
Guidelines · May 2026
Adult Myopia Progression: Epidemiology & Risk
How common is myopia progression in adults, which populations are most at risk, and what the longitudinal data says about late-onset and continuing progression.
7 min readRead article →
Global Epidemiology · May 2026
Myopia in Singapore: Why It Happens, Who It Affects, and What's Being Done
Singapore has some of the highest myopia rates in the world — over 65% in young adults. Prevalence by age group, government screening programs, National Myopia Programme, and what parents should know.
8 min readRead article →
Guidelines · May 2026
Myopia Progression: What's Normal, What's Fast, and When to Act
Age-stratified normative progression rates from Tideman 2018. Is 1 diopter per year fast? What axial length growth warrants treatment? Evidence-based thresholds explained.
7 min readRead article →
Treatment · May 2026
Compare Myopia Treatments — All Options Side by Side (2026)
MiSight vs Stellest vs Ortho-K vs atropine vs DIMS — efficacy, age range, mechanism, cost, and practical prescribing guidance. Based on Chamberlain 2019, Bao 2022, LAMP, and ATOM2.
6 min readRead article →
Treatment · Coming soon
Ortho-K vs Atropine 0.01%: Which First?
Patient selection criteria, combination sequencing, and the evidence for each as monotherapy in moderate progressors.
Guidelines · Coming soon
Pre-Myopia Risk Factor Checklist
A structured clinical checklist for identifying at-risk children before manifest myopia onset, based on IMI 2025 and BHVI criteria.

New articles in your inbox

One email per new clinical resource published. No marketing, no spam.